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S urgical and medical treatments for congenital heart disease (CHD) have improved over time,  
and nowadays over 90% of pediatric CHD patients are 
expected to reach adulthood [1 , 2].  However,  despite 
receiving appropriate treatment in childhood,  individ-
uals with adult CHD (ACHD) are not necessarily com-
pletely cured [2].  Following up these adult patients is 
recognized as an important medical and social issue.  In 
Japan,  the number of ACHD outpatient clinics oper-
ated by cardiologists has increased,  but it remains 
unknown what types of cardiovascular events occur in 
patients with ACHD.  We conducted the present study 
to investigate the types and frequency of cardiovascular 
events in ACHD patients and to assess the influence of 
the patients’ disease complexity on cardiovascular 
events requiring hospitalization.
Patients and Methods
Patient population. This was a retrospective,  
observational cohort study.  All ACHD patients who 
were referred from other hospitals or transferred from 
the departments of pediatric surgery and pediatric car-
diology to the ACHD Center of Okayama University 
Hospital between August 2014 and September 2017 
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The follow-up of patients with adult congenital heart disease (ACHD) at a specialized medical unit is necessary 
for the patients’ appropriate medical care.  However,  limited information is available about cardiovascular 
events among ACHD patients.  Here we investigated the type and frequency of cardiovascular events in ACHD 
patients in relation to disease complexity.  We retrospectively analyzed the cases of 535 patients (median age 35 
years) referred to our ACHD center between 2014 and 2017.  We divided the patients into 3 groups based on 
their disease complexity.  To evaluate the relationship between disease complexity and cardiovascular events,  we 
performed univariate and multivariate survival analyses.  The Simple,  moderate,  and complex disease groups 
accounted for 62%,  19%,  and 19% of the patients,  respectively.  Apart from events related to atrial septal defect 
(ASD) trans-catheter treatment,  the frequency of cardiovascular events was dependent on the disease complex-
ity (event-free survival rates at 3 years were 85%,  65%,  and 58%,  respectively).  The hazard ratios were 4.0 and 
5.1 in the moderate and complex groups,  respectively.  With the exception of scheduled transcatheter interven-
tion,  cardiovascular events were strongly related to the disease complexity of original heart disease.  However,  
cardiovascular events were not rare even in the simple ACHD group.
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were enrolled in this study.  Patients were eligible for the 
study if they were > 18 years of age.
Classification of ACHD complexity. We divided 
the ACHD patients into 3 groups based on their 
Bethesda disease complexity classification (complexity 
of primary diagnosis) [3 , 4] as follows: the Simple 
group was comprised of the cases of CHD with only 
simple lesions such as isolated valve disease (aortic,  
mitral,  or pulmonary stenosis and/or regurgitation),  
atrial septal defect (ASD),  ventricular septal defect 
(VSD),  patent ductus arteriosus (PDA),  and isolated 
coronary anomaly.  The Moderate group was the 
patients with CHD with moderate-complexity lesions 
such as atrioventricular septal defect,  coarctation of the 
aorta,  interrupted aortic arch,  Ebstein anomaly,  tetral-
ogy of Fallot (TOF),  and total/partial anomalous pul-
monary venous return.  The Complex group was the 
patients with CHD with highly complex lesions such as 
congenitally corrected transposition of the great arter-
ies,  transposition of the great arteries,  truncus arterio-
sus,  pulmonary atresia,  other congenital complex 
lesions including single ventricle,  tricuspid atresia,  and 
double-outlet ventricles.  Patients with Eisenmenger 
syndrome or Fontan physiology were included in 
Complex group regardless of their original heart dis-
eases.
Definition of cardiovascular events. We used the 
patients’ chart records in our search for cardiovascular 
events.  Our definition of cardiovascular events includ-
ed: death,  open cardiac surgery and unexpected hospi-
talizations due to heart failure,  arrhythmias,  pulmo-
nary hypertension or ischemic heart disease.  
Hospitalization for a scheduled catheter intervention 
was excluded as a cardiovascular event.  The diagnosis 
of heart failure was based on the clinical presentation of 
the modified Framingham Heart Failure criteria [5],  
and we identified patients with New York Heart 
Association class 3 or 4 symptoms.  Hospitalization for 
pulmonary hypertension was defined as the worsening 
of symptoms related to pulmonary hypertension and the 
addition of pulmonary hypertension-specific drugs [6].  
Indications for cardiac surgery were decided on the 
basis of guidelines of The Japanese Circulation Society 
(http://www.j-circ.or.jp/guideline/pdf/JCS2017_
ichida_h.pdf accessed March 2019),  The American 
Heart Association [3],  and The European Society of 
Cardiology [2].
Statistical analyses. All analyses were performed 
with SPSS25 (2017 release software by IBM,  Armonk,  
NY,  USA).  P-values < 0.05 were accepted as significant.  
Continuous variables are presented as the median (25-
75% interquartile range [IQR]),  and categorical vari-
ables are summarized as numbers and percentages.  The 
baseline characteristics of patients at their first visits 
were determined.  We used the Kruskal-Wallis test and 
the χ2-test when comparing multiple continuous vari-
ables and binary variables,  respectively.  Post hoc com-
parisons were analyzed with the Bonferroni correction.
To investigate the relationship between disease com-
plexity and cardiovascular events,  we performed a uni-
variate survival analysis with the log-rank test.  We used 
the Cox proportional hazards model to quantify the 
effects of disease complexity on the risk of cardiovascu-
lar events.  For the multivariate analysis,  variables were 
selected in advance of the analysis as clinically mean-
ingful factors including demographic factors (sex,  age,  
referral from other institutions),  co-morbidity factors 
(complication of pulmonary hypertension,  history of 
ventricular arrhythmia),  and representative laboratory 
data,  i.e.,  B-type natriuretic peptide (BNP) and the 
estimated glomerular filtration rate (eGFR).  ‘Time zero’ 
was the day of the patient’s first visit to our ACHD 
Center.  This study was approved by the Ethical Com-
mittee of Okayama University (approval no. 1707-004).
Results
Patient backgrounds. The disease distribution of 
the patients is shown in Table 1.  The 535 ACHD 
patients who visited the center during this period were 
classified as the Simple (n = 330,  62%),  Moderate 
(n = 102,  19%),  and Complex (n = 103,  19%) groups.  
ASD patients were the most common and accounted 
for 43%,  followed by TOF and VSD (9% and 8%,  
respectively).  Other diseases accounted for between 
0.4% and 5% of the patient series.  Four percent of the 
patients had undergone a Fontan operation.  Eisen-
menger syndrome patients accounted for 0.5%.
The characteristics of patients are summarized in 
Table 2.  The median age of all patients was 35 years 
(IQR 22-58 years),  and the patients in the Simple group 
were the oldest.  Most of the patients in the Simple 
group were referred from other hospitals for the cathe-
ter treatment of ASD or PDA.  Most of the patients in 
the Moderate and Complex groups were transferred 
from the pediatric department in our hospital.  Two 
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percent of the patients had a history of ventricular 
arrhythmia,  4% of the patients had pulmonary hyper-
tension,  and 0.6% of the patients had Eisenmenger 
syndrome.  The median BNP level at the first visit was 
lower in the Moderate group compared to the Simple 
and Complex groups.  However,  the eGFR in the 
Simple group was significantly lower than those in the 
two other groups,  probably due to the Simple group 
patients’ advanced ages at their first visits.
The influence of ACHD complexity on cardiovascu-
lar events requiring hospitalization. During the 
median follow-up of 537 days,  corresponding to 787 
patient years,  91 (17%) patients had 158 complications 
in total.  Eight percent of the patients in the Simple 
group,  23% in the Moderate group,  and 30% in the 
Complex group experienced a cardiovascular event 
during their follow-up.
Figure 1 shows the cardiovascular event-free sur-
vival curves from death,  open cardiac surgery,  or car-
diovascular events requiring unexpected hospitalization 
for treatment.  A decrease in cardiovascular event-free 
survival within the first few months after the patients’ 
first visit was observed in all 3 groups.  The cardiovas-
cular event-free survival curve in the Simple group was 
almost flat after 180 days,  whereas the curves in the 
Moderate and Complex groups progressively decreased.  
Cardiovascular events were strongly associated with 
ACHD complexity,  and the 3-year cardiovascular 
event-free rate was significantly lower in the Moderate 
and Complex groups: 65% in the Moderate group,  58% 
in the Complex group,  and 85% in the Simple group 
(p = 0.009 the Simple group vs the Moderate group,  
p = 0.002 the Simple group vs the Complex group).
The Cox proportional hazard model revealed that 
with reference to the Simple group,  the adjusted hazard 
ratio (HR) of ACHD complexity for cardiovascular 
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Table 1　 Distribution of disease
Simple 330 62%
ASD 231 43%
VSD 46 8%
Aortic valve disease 15 3%
PDA 13 3%
Pulmonary valve disease/right ventricular outlet 
stenosis 12 2%
Mitral valve disease 9 2%
Isolated coronary anormaly 4 0.6%
Moderate 102 19%
TOF 49 9%
CoA/IAA 20 4%
AVSD 16 3%
Ebstein 8 2%
TAPVR/PAPVR 6 1%
Other congenital heart diseases with moderate 
Complexity 3 0.5%
Complex 103 19%
SV/TA/DORV/DOLV 25 5%
Post Fontan procedure 22 4%
TGA 16 3%
cTGA 15 3%
PA-VSD/TOF-PA 13 2%
PA-IVS 7 0.3%
Eisenmenger syndrome 3 0.5%
PTA 2 0.4%
Table 2　 Baseline characteristics
Simple
(n＝330)
Moderate
(n＝102)
Complex
(n＝103)
Total number
(n＝535) p value
Demographic factors
　Age (years old) 49 [27-66] 22 [20-32] 24 [21-37] 35 [22-58] ＜0.001＊＊
　Male,  n (%) 128 (39) 51 (50) 50 (49) 229 (43) 0.06
　Reference from other Institutions,  n (%) 253 (77) 20 (20) 36 (35) 309 (58) ＜0.001＊＊
Co-morbidity factors
　Ventricular arrhythmia,  n (%) 2 (0.6) 6 (5.9) 5 (4.9) 13 (2.4) 0.002＊＊
　Pulmonary hypertension on drug,  n (%) 12 (3.6) 2 (1.0) 8 (7.8) 22 (4.1) 0.09
Laboratory data
　BNP (pg/ml) 32.1 [13.7-101.6] 24.2 [10.4-49.5] 36.4 [15.3-96.3] 31.7 [13.7-87.6] 0.01＊
　eGFR (mL/min/1.73 m2) 78.2 [63.5-93.7] 94.0 [83.6-109.4] 94.1 [78.1-109.4] 84.7 [69.3-100.0] ＜0.001＊＊
events requiring hospitalization was 4.0 (95% confi-
dence interval [CI]: 2.0-7.8,  p < 0.001) in the Moderate 
group and 5.1 (95%CI: 2.8-9.3,  p < 0.001) in the 
Complex group.  The three other significant risk factors 
were age (adjusted HR 1.3 per 10 years of age; 95%CI:  
1.1-1.5,  p = 0.04),  the comorbidity of pulmonary hyper-
tension requiring specific medication (adjusted HR 2.4,  
95%CI: 1.3-4.7,  p = 0.008),  and low eGFR (adjusted 
HR 0.9 per 10 ml/min/1.73 m2,  95%CI: 0.8-0.99,  
p = 0.03) (Table 3).
Details of the cardiovascular events. As shown in 
Fig. 2,  the proportion of causes of hospitalization varied 
by ACHD complexity,  but arrhythmia,  heart failure,  
and surgery were the most common cardiovascular 
events in each of the 3 patient groups.  On the whole,  
these three events accounted for 41%,  33%,  and 16% of 
all of the events,  respectively.
Although arrhythmias requiring hospitalization or 
any treatment were commonly documented in every 
group,  ventricular tachycardia with the risk of sudden 
death occurred only in the Moderate and Complex 
groups (one case of TOF,  one Ebstein anomaly,  one 
complete transposition of the great arteries,  and one 
pulmonary atresia with VSD).  Heart failure,  especially 
in the Complex group,  tended to be refractory,  and 
70% (7 of the 10) patients with heart failure in the 
Complex group needed hospitalization more than once.
Eight of the 12 cases (75%) with surgery in the 
Moderate group were for the reconstruction of the right 
ventricular outflow tract of TOF.  Two ischemic heart 
events occurred in elderly patients with arteriosclerosis 
risk factors without an anomalous origin of a coronary 
artery.
Two patients (0.12%) died during the observational 
period.  One was a 67-year-old male with unrepaired 
TOF.  The patient underwent the surgical implantation 
of a cardiac resynchronization therapy device for 
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Fig. 2　 Causes of hospitalization.  The causes of hospitalization depending on ACHD complexity are shown.  Transcatheter intervention 
was the most common cause in the Simple group,  with surgery the most common cause in the Moderate group,  and heart failure in the 
Complex group.  IHD,  ischemic heart disease; PH,  pulmonary hypertension.
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Fig. 1　 Event-free survival curves for cardiovascular events 
requiring hospitalization in relation to ACHD complexity (log-rank 
test).  The cardiovascular event-free survival curves of the Simple,  
Moderate,  and Complex ACHD groups are shown.  Events included 
death,  open cardiac surgery,  and unexpected hospitalizations due 
to heart failure,  arrhythmias,  pulmonary hypertension,  or ischemic 
heart disease.
severely deteriorated left ventricular function.  An 
unexpected massive hemorrhage due to pericardial 
adhesion occurred during the surgical procedure,  and 
he died 1 month later.  The other patient who died was a 
44-year-old male with tricuspid atresia and failed 
Fontan status,  complicated with liver cirrhosis and 
hepatic cancer.  The patient was repeatedly hospitalized 
due to right heart failure,  protein-losing enteropathy,  
and low output syndrome.  He died due to multiple 
organ failure.
Discussion
This was a retrospective observational study of 535 
ACHD patients referred to our ACHD center over a 
3-year period.  We found that increasing complexity of 
ACHD is associated with a greater risk of comorbidities 
regardless of ACHD treatment in childhood.
ACHD outpatient clinics have become increasingly 
widespread in Japan in the past decade [7],  and our 
present findings provide an overview of a single territo-
rial ACHD center.  There have been only a few explor-
ative investigations of ACHD complexity and associated 
cardiovascular events [8 , 9].  Diller et al.  evaluated the 
survival prospects and circumstances of death of ACHD 
patients,  and they reported that the mortality ratio of 
moderate or complex congenital heart disease ranged 
from 1.7 to 3.3 compared with a sex- and aged-matched 
general population [10].  Engelfriet et al.  reported sub-
stantial morbidity among ACHD patients,  even with 
only simple complexity disease [11].  Our present data 
are consistent with these observations; we observed 
that the disease complexity of ACHD had a significant 
impact on the number of cardiovascular events requir-
ing hospitalization.
We also observed that the details of the patients’ car-
diovascular events varied depending on ACHD com-
plexity.  The Simple group included patients referred to 
our hospital for trans-catheter ASD/PDA closure.  
Although it is true that a substantial number of patients 
need a trans-catheter closure of defects after they 
develop heart failure or dilation of the right ventricle,  
we note that in Japan the trans-catheter closure proce-
dure is performed in only a limited number of regis-
tered facilities.  However,  importantly,  as many as 15% 
of the patients in our Simple group had cardiovascular 
events other than this procedure,  suggesting that no 
ACHD patient should be lost during following-up.
Arrhythmias were commonly observed in every 
group as in previous studies [12].  More severe arrhyth-
mias occur in complex ACHD patients due to multiple 
mechanisms such as intra-cardiac repair scars,  congen-
ital conduction abnormalities,  or persistent hemody-
namic abnormalities [13].  However,  Bouchardy et al.  
reported that both supraventricular arrhythmias and 
ventricular arrhythmias influenced mortality [14].  This 
may indicate that the monitoring of arrhythmias in 
ACHD patients can be important as a surrogate marker 
of mortality risk.
Heart failure was also a common reason for hospi-
talization.  Negishi et al.  reported that 86% of their 
study’s ACHD patients requiring heart failure hospital-
ization had complex forms of congenital heart disease 
[15].  Heart failure,  especially in more complex disease,  
emerges as a final expression of various disorders such 
as uncontrollable arrhythmias,  reduced ventricular 
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Table 3　 Adjusted hazard ratio of risk factors Inﬂuencing cardiac events requring hospitalization
AHR 95% upper CI 95% lower CI p-value
Complexity
Simple (reference) 1 -
Moderate 3.95 1.99 7.84 ＜0.001
Complex 5.14 2.84 9.3 ＜0.001
Age (10 years) 1.27 1.08 1.5 0.04
Female 0.85 0.55 1.32 0.47
Referred from other institutions 1.75 0.95 3.21 0.07
Pulmonary hypertension 2.44 1.26 4.72 0.008
Ventricular arrythmia 0.97 0.37 2.55 0.95
BNP (10 pg/ml) 1 0.99 1.01 0.97
eGFR (10 ml/min/1.73 m2) 0.9 0.81 0.99 0.03
function,  and/or valvular diseases.  Patients with com-
plex lesions tended to have refractory heart failure and 
repeat hospitalization to receive palliative therapy.
A multidisciplinary approach is the key to the opti-
mal management of ACHD patients,  and this approach 
highlights the need for territorial referral centers in this 
field.  The incidence of heart failure after the Fontan 
procedure progresses with age,  reaching nearly 50% by 
adulthood [16 , 17].  Although the patient cohorts of 
these previous studies cannot be easily compared with 
our patient series,  23% of the patients with Fontan 
physiology in our study had heart failure,  and thus the 
incidence of heart failure may increase further as these 
patients continue to age.
A first or repeat surgery is often required in patients 
with moderate or complex ACHD.  For example,  
Ebstein anomaly or corrected transposition of the great 
arteries result in only insignificant symptoms in child-
hood but require surgery later in life as these conditions 
develop.  The majority of repeat surgeries in the present 
study were for TOF with severe pulmonary regurgita-
tion.  The importance of repeated surgical procedures 
should thus be recognized,  and this also highlights the 
need for multimodal assessment including CT,  MRI,  
cardiopulmonary exercise,  and electrophysiological 
evaluations at ACHD-specific facilities.
We also evaluated the influence of representative 
factors on cardiovascular events,  and in our cohort,  the 
patient’s age at the first visit,  the comorbidity of pulmo-
nary hypertension,  and the eGFR were detected as 
independent factors.  Although there are unmeasured 
compounding factors due to CHD variation,  these 
results are reasonable and compatible with previous 
studies [18-20].  To identify disease-specific risk factors,  
further investigations using ‘big data’ with multiple 
variables are needed.
Limitation. This was a retrospective cohort study 
from a single center with a relatively small patient pop-
ulation.  The follow-up period was limited and it was 
thus not possible to evaluate the risks of cardiovascular 
events or mortality in ACHD patients.  Each disease 
classification does not reflect the disease severity com-
pletely; rather,  each classification reflects a majority of 
ACHD patients with comorbidity or associated cardiac 
lesions.
In conclusion,  the results of our analyses demon-
strate that the disease complexity of ACHD has a signif-
icant impact on the number of cardiovascular events 
requiring hospitalization during a 3-year observation 
period.  However,  cardiovascular events were not rare 
even in the simple-complexity group.  A higher inci-
dence of hospitalization was observed in the patients 
with higher age,  those with pulmonary hypertension,  
and those with renal dysfunction.  Arrhythmia was the 
most frequent event in the Simple group,  surgery in the 
Moderate,  and heart failure in the Complex group.  
Regular follow-up at specialized ACHD centers and a 
regional network are essential to monitor these various 
events in ACHD patients and to supply optimal care.  
Further studies,  including multi-institutional prospec-
tive surveys,  are expected to identify disease-specific 
risk factors.
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